CAR-T Therapy for Richter’s Transformation
February 22, 2024
Chimeric antigen receptor T-cell (CAR-T) therapy can provide durable remissions in a subset of patients with Richter’s transformation.
Chimeric antigen receptor T-cell (CAR-T) therapy can provide durable remissions in a subset of patients with Richter’s transformation.
Early results from a phase 1b/2 trial show that epcoritamab has a manageable safety profile and an encouraging response rate in patients with Richter syndrome.
Duvelisib plus venetoclax is a time-limited, all-oral regimen active in relapsed/refractory chronic lymphocytic leukemia (CLL) and Richter syndrome.
Our own Dr. Brian Koffman interviewed Dr. Nirav Shah, Associate Professor of Medicine at Medical College of Wisconsin, focusing on hematological malignancies. They discussed the latest results from a clinical trial of pirtobrutinib, a new reversible Bruton tyrosine kinase (BTK) inhibitor, for treating Richter transformation.
What follows is our patient-friendly summary of this research: Richter’s syndrome (RS), also known as Richter’s transformation, is a rare complication of chronic lymphocytic leukemia (CLL). It transforms into what is usually an aggressive lymphoma with a dismal prognosis.
and President, interviewed Dr. Alexey Danilov, Associate Director of the Toni Stephenson Lymphoma Center at City of Hope in Duarte, CA. They discussed the development of Richter transformation after chimeric antigen receptor T-cell (CAR-T) therapy.
Richter’s Transformation Richter’s Transformation First described in 1928, Richter’s Transformation (RT), also called Richter’s Syndrome (RS), occurs when CLL / SLL changes into a related but much more aggressive large cell
Profiling the metabolites produced by cells in Richter transformation could help researchers develop new ways to target therapies in the future.
By never freezing the locally produced CAR-T cells, disappointing response rates for relapsed/refractory CLL and Richter’s Syndrome patients are greatly improved